Literature DB >> 5280527

The reaction of glucagon with its receptor: evidence for discrete regions of activity and binding in the glucagon molecule.

M Rodbell, L Birnbaumer, S L Pohl, F Sundby.   

Abstract

Des-histidine-glucagon (DH-glucagon, glucagon(2-29)) does not activate the glucagon-sensitive adenylate cyclase system present in either liver plasma membranes or in fat-cell "ghosts", but inhibits the response of these systems to submaximal concentrations of glucagon. DH-glucagon also inhibits, competitively, the binding of [(125)I]glucagon to its receptor in liver plasma membranes. Amino-terminal fragments of glucagon (glucagon(1-21), glucagon(1-23)) and carboxy-terminal fragments (glucagon(20-29), glucagon(22-29)) failed to activate adenylate cyclase, to inhibit the response of the enzyme to glucagon, or to compete with labeled glucagon at its receptor. It is concluded that the amino-terminal histidine residue of glucagon is essential for biological activity and that a hydrophobic near-carboxy-terminal region (residues 22-27) is essential for binding of glucagon to its receptor. Amino-terminal histidine may also contribute to the binding of glucagon, since the apparent affinity of DH-glucagon for the receptor is only about one-sixth that of glucagon. Thus, essentially the entire molecule of glucagon must be considered to be the biologically active species.Because, as shown elsewhere, the binding of glucagon to its receptor shows characteristics of hydrophobic bonding, and because certain detergents induce conformational changes in the carboxy-terminal binding region of glucagon, the binding is probably of a lipophilic type.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5280527      PMCID: PMC389078          DOI: 10.1073/pnas.68.5.909

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

1.  The relationship of epinephrine and glucagon to liver phosphorylase. III. Reactivation of liver phosphorylase in slices and in extracts.

Authors:  T W RALL; E W SUTHERLAND; W D WOSILAIT
Journal:  J Biol Chem       Date:  1956-01       Impact factor: 5.157

2.  The contribution of hydrophobic bonds to the thermal stability of protein conformations.

Authors:  H A SCHERAGA; G NEMETHY; I Z STEINBERG
Journal:  J Biol Chem       Date:  1962-08       Impact factor: 5.157

3.  Adenyl cyclase in fat cells. 3. Stimulation by secretin and the effects of trypsin on the receptors for lipolytic hormones.

Authors:  M Rodbell; L Birnbaumer; S L Pohl
Journal:  J Biol Chem       Date:  1970-02-25       Impact factor: 5.157

4.  A simple, sensitive method for the assay of adenyl cyclase.

Authors:  G Krishna; B Weiss; B B Brodie
Journal:  J Pharmacol Exp Ther       Date:  1968-10       Impact factor: 4.030

5.  Adenyl cyclase in fat cells. 1. Properties and the effects of adrenocorticotropin and fluoride.

Authors:  L Birnbaumer; S L Pohl; M Rodbell
Journal:  J Biol Chem       Date:  1969-07-10       Impact factor: 5.157

6.  Effects of chemical and enzymatic modifications of glucagon on its activation of hepatic adenyl cyclase.

Authors:  A M Spiegel; M W Bitensky
Journal:  Endocrinology       Date:  1969-10       Impact factor: 4.736

7.  Adenyl cyclase in fat cells. II. Hormone receptors.

Authors:  L Birnbaumer; M Rodbell
Journal:  J Biol Chem       Date:  1969-07-10       Impact factor: 5.157

8.  Isolation of an organ specific protein antigen from cell-surface membrane of rat liver.

Authors:  D M Neville
Journal:  Biochim Biophys Acta       Date:  1968-04-09

9.  Interrelationship of glucagon, insulin and glucose. The insulinogenic effect of glucagon.

Authors:  E Samols; G Marri; V Marks
Journal:  Diabetes       Date:  1966-12       Impact factor: 9.461

10.  Correlation of adrenocorticotropic activity of ACTH analogs with degree of binding to an adrenal cortical particulate preparation.

Authors:  K Hofmann; W Wingender; F M Finn
Journal:  Proc Natl Acad Sci U S A       Date:  1970-10       Impact factor: 11.205

View more
  11 in total

1.  A radioreceptor-assay for glucagon: binding of enteroglucagon to liver plasma membranes.

Authors:  J J Holst
Journal:  Diabetologia       Date:  1975-06       Impact factor: 10.122

Review 2.  Interactions polypeptide hormones with cell membrane specific receptors: studies with insulin and glucagon.

Authors:  P Freychet
Journal:  Diabetologia       Date:  1976-05       Impact factor: 10.122

3.  Membrane receptors for hormones and neurotransmitters.

Authors:  C R Kahn
Journal:  J Cell Biol       Date:  1976-08       Impact factor: 10.539

4.  Thermodynamics of the self-association of glucagon.

Authors:  S Formisano; M L Johnson; H Edelhoch
Journal:  Proc Natl Acad Sci U S A       Date:  1977-08       Impact factor: 11.205

5.  A new bioassay for glucagon.

Authors:  G Gagnon; D Regoli; F Rioux
Journal:  Br J Pharmacol       Date:  1978-09       Impact factor: 8.739

6.  Structural transitions and interactions in the early stages of human glucagon amyloid fibrillation.

Authors:  Balakrishnan S Moorthy; Hamed Tabatabaei Ghomi; Markus A Lill; Elizabeth M Topp
Journal:  Biophys J       Date:  2015-02-17       Impact factor: 4.033

Review 7.  Structure-conformation-activity studies of glucagon and semi-synthetic glucagon analogs.

Authors:  V J Hruby
Journal:  Mol Cell Biochem       Date:  1982-04-16       Impact factor: 3.396

8.  ACTH antagonists.

Authors:  K Hofmann; J A Montibeller; F M Finn
Journal:  Proc Natl Acad Sci U S A       Date:  1974-01       Impact factor: 11.205

9.  Insulin receptors in the liver: specific binding of ( 125 I)insulin to the plasma membrane and its relation to insulin bioactivity.

Authors:  P Freychet; J Roth; D M Neville
Journal:  Proc Natl Acad Sci U S A       Date:  1971-08       Impact factor: 11.205

10.  Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils.

Authors:  Satomi Onoue; Keiichi Ohshima; Kazuhiro Debari; Keitatsu Koh; Seiji Shioda; Sumiko Iwasa; Kazuhisa Kashimoto; Takehiko Yajima
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.